Adage Capital Partners
ACET icon

Adage Capital Partners’s Adicet Bio ACET Stock Holding History

Adage Capital Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Hold
274,375
– – ﹤0.01% 863
2026
Q1 		$1.87M Hold
274,375
– – ﹤0.01% 844
2025
Q4 		$2.31M Buy
+274,375
New +$3.03M ﹤0.01% 826
2021
Q3 		– Sell
-30,500
Closed -$5.02M – 1016
2021
Q2 		$5.02M Hold
30,500
– – 0.01% 824
2021
Q1 		$6.38M Buy
+30,500
New +$7M 0.01% 770

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Adage Capital Partners's ACET Position: Q2 2026 in Review

Adage Capital Partners held its Adicet Bio (ACET) position steady in Q2 2026 at 274,375 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Adage Capital Partners first reported a position in ACET in Q1 2021 and has held it in 5 quarters since. The position peaked at $6.38M in Q1 2021. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Adage Capital Partners held 274,375 shares of Adicet Bio worth $2.37M as of Q2 2026.
  • Adage Capital Partners left its Adicet Bio share count unchanged in Q2 2026.
  • Adicet Bio made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #863 holding.
  • Adage Capital Partners first reported a position in Adicet Bio in Q1 2021 and has held it in 5 quarters since.
  • Adage Capital Partners's Adicet Bio position peaked at $6.38M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.